Versartis Secures $11,000,000 Series A Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    303 Twin Dolphin Drive Redwood City, CA 94065
  • Company Description
    Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The funds raised will be used to progress its novel compounds into human clinical trials.
  • M&A Terms
  • Venture Investor
    Index Ventures

Trending on Xconomy